Bank of Nova Scotia Has $8.44 Million Stake in Regeneron Pharmaceuticals, Inc. (REGN)
Bank of Nova Scotia lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,187 shares of the biopharmaceutical company’s stock after selling 230 shares during the period. Bank of Nova Scotia’s holdings in Regeneron Pharmaceuticals were worth $8,441,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of REGN. Victory Capital Management Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 24.2% during the 1st quarter. Victory Capital Management Inc. now owns 3,567 shares of the biopharmaceutical company’s stock worth $1,382,000 after acquiring an additional 694 shares during the period. Teachers Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 4.4% during the 1st quarter. Teachers Advisors LLC now owns 98,126 shares of the biopharmaceutical company’s stock worth $38,025,000 after acquiring an additional 4,136 shares during the period. Rothschild Asset Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $441,000. Ngam Advisors L.P. raised its holdings in shares of Regeneron Pharmaceuticals by 22.0% during the 1st quarter. Ngam Advisors L.P. now owns 129,220 shares of the biopharmaceutical company’s stock worth $50,074,000 after acquiring an additional 23,324 shares during the period. Finally, Sustainable Growth Advisers LP raised its holdings in shares of Regeneron Pharmaceuticals by 13.2% during the 1st quarter. Sustainable Growth Advisers LP now owns 513,569 shares of the biopharmaceutical company’s stock worth $199,013,000 after acquiring an additional 59,900 shares during the period. Institutional investors and hedge funds own 67.41% of the company’s stock.
Several research analysts have recently commented on the company. Zacks Investment Research lowered Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Morgan Stanley reiterated an “equal weight” rating and set a $490.00 price target (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Jefferies Group LLC reiterated a “hold” rating and set a $500.00 price target (up previously from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. SunTrust Banks, Inc. reiterated a “hold” rating and set a $435.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, October 2nd. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $540.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, September 29th. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $489.92.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded down 0.94% during trading on Friday, hitting $442.96. The stock had a trading volume of 718,075 shares. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The company has a market cap of $46.97 billion, a P/E ratio of 44.44 and a beta of 1.62. The stock’s 50-day moving average price is $457.32 and its 200-day moving average price is $454.85.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the firm earned $2.82 earnings per share. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.95 EPS for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Sanofi acquired 166,415 shares of the stock in a transaction on Thursday, August 24th. The shares were acquired at an average price of $480.93 per share, with a total value of $80,033,965.95. The disclosure for this purchase can be found here. In the last quarter, insiders sold 89,468 shares of company stock valued at $42,312,448. Insiders own 10.80% of the company’s stock.
WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/bank-of-nova-scotia-has-8-44-million-stake-in-regeneron-pharmaceuticals-inc-regn/1630230.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.